. 2020 Jul 1;15(7):e0235091. doi: 10.1371/journal.pone.0235091

Table 2. Univariate analyses of covariance in EQ VAS, DLQI and PBI.

		EQ VAS			DLQI			PBI
		M±SD			M±SD			M±SD
Anogenital psoriasis	Male	62.23±22.62			8.82±6.76			2.33±1.14
Anogenital psoriasis	Female	59.92±24.87			9.02±7.11			2.46±1.12
Control group	Male	67.71±20.43			6.50±6.04			2.49±1.11
Control group	Female	63.52±21.41			7.57±6.29			2.51±1.14
		F	P	Ŋ²_p	F	P	Ŋ²_p	F	P	Ŋ²_p
Main effect of anogenital involvement		1.60	0.207	0.001	9.27	0.002	0.006	2.03	0.154	0.001
Main effect of gender		13.85	< 0.001	0.009	10.22	0.001	0.006	0.21	0.646	0.000
*Interaction effect anogenital involvement gender**		0.95	0.329	0.001	3.56	0.059	0.002	1.54	0.215	0.001

EQ VAS, EuroQoL visual analogue scale (0 = worst health state to 100 = best health state); DLQI, Dermatology Life Quality Index (0 = minimum impairment to 30 = maximum impairment); PBI, Patient Benefit Index (0 = no benefit to 4 = maximal benefit); M, mean; SD, standard deviation; F, two-way ANCOVA; Ŋ²_p, partial eta-square.